Science-based grouping of nanoparticles for industrial application - - PowerPoint PPT Presentation

science based grouping of nanoparticles for industrial
SMART_READER_LITE
LIVE PREVIEW

Science-based grouping of nanoparticles for industrial application - - PowerPoint PPT Presentation

Science-based grouping of nanoparticles for industrial application of safe-by-design Katarzyna Odziomek, Tomas Puzyn, Piotr Urbaszek, Andrea Haase, Christian Riebeling, Agnieszka Gajewicz, Muhammed A. Irfan, Robert Landsiedel, Meike van der


slide-1
SLIDE 1

Science-based grouping of nanoparticles for industrial application of safe-by-design

Katarzyna Odziomek, Tomas Puzyn, Piotr Urbaszek, Andrea Haase, Christian Riebeling, Agnieszka Gajewicz, Muhammed A. Irfan, Robert Landsiedel, Meike van der Zande, and Hans Bouwmeester

slide-2
SLIDE 2

“To bridge the Mode of Action based computational modelling to the demands of grouping and safe by design of nanoparticles, and make it applicable for industry”.

Objective

2

slide-3
SLIDE 3

Are there (any) principles for grouping of NM?

  • ..not every chemical needs to be tested for every endpoint...overall

data for that category should prove adequate to support a hazard assessment... (OECD, 2014)

  • Grouping should take into account all aspects of NM life cycle.. (Arts

et al., 2014)

  • Structure and material properties, exposure, uptake and kinetics,

initiating cellular effects or apical effects.. (ECETOC 2014)

Oomen et al 2014

3

slide-4
SLIDE 4

Establishing science-based criteria for grouping

4

Adapted from Agnes Oomen et al. 2014 In „Safety of nanomaterials along their life-cycle“ pp 358 – 379 ISBN 978-1-46-656786-3, 2014

slide-5
SLIDE 5

ECETOC Grouping Strategy

5

Arts et al., 2015, A decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping). Regul Toxicol Pharmacol. 2015 Mar 15;71(2 Suppl):S1-27. doi: 10.1016/j.yrtph.2015.03.007.

slide-6
SLIDE 6

Grouping Concepts

6

 No single property groups all materials – Need a multi-perspective grouping & testing strategy

Multi-perspective grouping

Refinement of grouping criteria

slide-7
SLIDE 7

Tiered Testing

7

slide-8
SLIDE 8

Panel of nanoparticles

8

Name Size SizeDLSw SSA Zeta XPSC XPSNa BaSO4.NM220 32.00 350.00 41.00

  • 39.00

17.00 0.00 CeO2 200.00 N/A 33.00 6.00 9.00 0.00 CeO2.Al 81.00 N/A 46.00 18.00 9.00 0.00 CeO2.NM211 12.00 N/A 33.00 16.00 28.70 0.00 CeO2.NM212 40.00 N/A 27.00 42.00 79.90 0.00 SiO2.NH3 15.00 42.00 200.00 0.00 73.10 0.00 SiO2.PEG 15.00 50.00 200.00

  • 26.00

73.60 0.00 SiO2.PO3 15.00 40.00 200.00 42.90 77.10 0.00 SiO2.UNMOD 15.00 40.00 200.00

  • 39.00

0.00 0.00 TiO2.NM105 50.00 478.00 51.00

  • 17.00

0.00 0.00 TiO2.TLSF 50.00 N/A 100.00

  • 3.00

5.00 0.50 ZrO2 42.50 N/A 24.90

  • 12.00

4.00 1.00 ZrO2.ACR 9.00 9.00 117.00

  • 39.00

9.00 0.50 ZrO2.NH3 10.00 315.00 105.00

  • 3.90

9.00 0.00 ZrO2.PEG 9.00 27.00 117.00

  • 7.80

19.00 0.00 ZrO2.TOD 9.00 9.00 117.00

  • 6.50

19.00 0.00 DPP.BULK 200.00 N/A 42.00

  • 11.40

0.00 0.00 DPP.NANO 400.00 N/A 64.00

  • 12.30

0.00 0.00 DPP.RED 43.00 N/A 30.00

  • 16.00

11.00 0.00

slide-9
SLIDE 9

With variations in surface modifications

9

slide-10
SLIDE 10

10

DPP Orange 1 (bulk) DPP Orange 2 (nano) Pigment Red 254- 2 (nano) MWNT NM400 Graphen e Graphen e nano- platelets Carbon black SiO2- naked SiO2 PEG SiO2 Amino SiO2 Phosphat e SiO2 FITC CeO2 NM212 CeO2 NM211 CeO2 Al-doped CeO2 BaSO4 NM220 ZnO NM111 ZnO NM110 TiO2 NM105 TiO2 (T- Lite SF) ZrO2.Acr ylate ZrO2.PE G ZrO2.Am ino ZrO2.TO Dacid AG50 AG50.mo no AG200.m

  • no

AG50.citr ate Ag.Braak uis Ag.Braak uis Ag.Braak uis Ag.Braak uis ZrO2 CuO

Material Properties Particle size DistributionTE M/SEM: Primary Particle Diameter 0.3-3 µm x 70-200 nm (TEM) 30-400 nm x 10-50 nm (TEM) 43 nm 15 nm Fiber Up to10 µm Flakes Up to 30 µm Flakes 50-100 nm Globular 15 nm 15 nm 15 nm 15 nm 25 nm 40 nm 4-15 nm Up to 200 nm Globular 2-160 nm Globular 32nm 80 nm Globular 80 15x50 nm 50x10 nm Fiber 9 nm 9 nm 10 nm 9 nm 7 nm 97 nm 134 nm 20 nm 18 nm 34 nm 60 nm 134 nm 25-60 nm 10 nm Surface Area (BET/Hg intrusion) 42 m²/g 64 m²/g 30 m²/g 161 m2/mg 131 m2/mg 74 m2/mg 32 m2/mg 200 m2/g 200 m2/g 200 m2/g 200 m2/g 178 m2/g 30 m²/g (Hg) 27 m²/g (BET) 33 m2/g 33 m2/g 46 m2/g 41 m2/g 12 m2/g 12 m2/g 51 m2/g 100 m2/g 117 m2/g 117 m2/g 105 m2/g 117 m2/g 86 m2/g 6.2 m2/g 4.5 m2/g 30 m2/g 32 m2/g 17 m2/g 9 m2/g 1 m2/g 24.9 m2/g N/A Surface Chemistry (XPS element %) C 73.1 Cl 9 N 9.5 O 8.4 C 73.6 Cl 8.8 N 8.7 O 8.8 C 77.1 O 10.9 N 5.9 Cl 6.1 C 99 O1 C 84.1 O 8.8 S 5.4 Na 0.6 Si 0.4 Cl 0.6 C 84.3 O 9.0 S 1.7 Na 3.0 Ca 1.5 Si 0.6 C 98 O 1 S 1 Cl <1 O 66 Si 29 C 4 Na 1 PEG identified (SIMS) Amino identified (SIMS) O 66 Si 29 C 5 Na 0,5 PO2,PO3 fragments N/A C 79.9 O 17.7 Ce 2.4 Ce 28.7 O 57.2 C 14.1 Ce 16 O 61 C 9 Al 9 Zr 5 Ce 21 Al 9 O 56 C 9 Zr 4 N 1 O 52 Ba 13 C 17 S 11 Cl, P 3 N 1 O 38 Zn 35 C 20 Cl 3 Na 3 O 38 Zn 35 C 30 Cl 3 Na 3 Ti 16 O 63 C 9 Al 7 Si 5 Na <1 Ti 16 O 63 C 9 Al 7 Si5 Na <1 dimethicone / methicone copolymer as coating Zr 23 O 58 C 19 SIMS: expected acrylic acid PEG identified (SIMS) Amino identified (SIMS) Zr 24 O 63 C 11 N 0.7 S 0.2 SIMS: expected trioxadecan
  • ic acid
C 63 O 24 Ag 14 C 59 O 18 Ag 16 Na 8 C 77 O 10 Ag 12 Na 1 N 1 C 21 O 24 Ag 62 Na 2 N/A N/A N/A N/A Zr 24 O 53 C 19 (C-C, C-O, O-C = O) N 3 Al 1 N/A Zeta Potential (pH 7.4)
  • 11.4 mV
  • 12.3 mV
  • 16 mV
N/A N/A N/A N/A
  • 39 mV
  • 26 mV
0 mV
  • 42,9 mV
N/A 42 mV 16 mV 6 mV 18 mV
  • 39 mV
N/A 20 mv
  • 17 mV
  • 3 mV
  • 39 mV
  • 7.8 mV
  • 3.9 mV
  • 6.5 mV
  • 20 mV
  • 7 mV
  • 7 mV
  • 45 mV
  • 45 mV
  • 45 mV
  • 45 mV
  • 45 mV
  • 12 mV
N/A Dustiness (Rotating dr um mg/kg) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Inhalable 2845 Respirable 66 N/A N/A N/A Inhalable 450 Respirable 80 Inhalable 1546 Respirable 70.6 N/A Inhalable 1020±20 Respirable 28±10 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Bio-Physical Interaction Surface Reactivity (Electron Spin Resonance ESR) N/A N/A N/A N/A N/A N/A N/A CPH 4 DMPO 11 CPH 1 DMPO 11 CPH 1 DMPO 21 CPH 2.2 DMPO 19 N/A N/A N/A N/A N/A CPH 2 DMPO 2 N/A CPH 22 DMPO 12 CPH 0,82 DMPO 3 N/A CPH 1 DMPO 3.6 CPH 1,5 DMPO 1.7 CPH 1 DMPO 3.5 CPH 0.54 DMPO 0.94 CPH 8 DMPO 0.50 CPH 45 DMPO 0.4 CPH 72 DMPO 0.48 N/A N/A N/A N/A N/A N/A N/A Dissolution/ Biopersistence N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A (Water) 0.002 wt% (DMEM/FCS ) <0.001 wt% (PSF) <0.001 wt% (PBS) <0.001 wt% (FassiF) <0.001 wt% (0.1n HCl) 0.02 wt% (Water) <0.001 wt% (DMEM/FCS ) <0.001 wt% (PSF) <0.001 wt% N/A N/A (PSF) 0.07 wt% (PBS) 0.12 wt% (FassiF) 0.1 wt% (0.1n HCl) 1.02 wt% N/A N/A (PSF) 0.15 wt% (PBS) 0 wt% (FassiF) 0 wt% (0.1n HCl) 0 wt% N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Solubility (ions) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Ce <0.1 ppm Ce <0.1 ppm Ce, Al <0.1 ppm Ba 6 ppm Soluble at pH<6 Soluble at pH 4.5 Ti <0.1 ppm Soluble at pH <6 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Zr <0.1 ppm N/A Dispersibility (D50): N/A N/A (PSF) 9.5 µm (PBS) 7.8 µm (0.1M HCl) 16 µm very stable even in PSF (Water) Agglomerate <0.01 wt% below 100 nm (DMEM/FCS ) 77000 nm Water) Agglomerate <0.01 wt% below 100 nm (DMEM) N/A (Water) Agglomerate <0.01 wt% below 100 nm (DMEM) N/A (Water) Agglomerate 1920 nm <0.1 wt% below 100 nm (DMEM/FCS ) 67µm N/A N/A N/A N/A N/A (Water) 432 nm (Water) 2839 nm N/A N/A (Water) 116 nm (DMEM/FCS ) 285 nm (Water) Agglomerate <0.01 wt% below 100 nm (DMEM/FCS ) 550 nm N/A (Water) 2700 nm <0.1 wt% below 100 nm (DMEM/FCS ) >>2 µm N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Lipid Affinity (DPPG/DOPG/ DPPG) N/A N/A N/A N/A N/A N/A N/A 0.95 0.90 1.05 0.90 N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.01 6.1 35.7 28.5 0.01 0.05 0.06 0.09 0.09 0.09 0.09 0.09 N/A N/A Cytochrome C Assay N/A N/A Biokinetics Dermal Penetration N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A No dermal penetration No significant dermal penetration N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Lung Deposition (%
  • f
concentration) N/A N/A N/A N/A N/A N/A N/A 2 6 8 5 N/A 8 15 15 8 6 N/A N/A 3 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Translocation N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Liver Lung Spleen Kidneys Testes Epididymis Brain Lungs Bone Cecum Intestines Spleen Stomach Kidneys Plasma Heart Brain RBC Skeletal Liver Skin Testes N/A N/A Liver Spleen Lung Kidneys N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Clearance (% after 21 days recovery) N/A N/A N/A N/A N/A N/A N/A 39 49 42 39 N/A N/A 5 5 7 77 N/A 16 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Early Biological Effect Vector Model (x fold increase) N/A N/A N/A N/A N/A N/A N/A 18.34 6.26 14.37 7.47 N/A N/A N/A N/A N/A 4.19 N/A 15.22 5.92 N/A 8.93 7.93 5.50 6.08 16.77 12.08 5.24 10.51 N/A N/A N/A N/A N/A N/A Cytotoxicity: N/A N/A N/A N/A N/A N/A Decreased metabolic activity LDH release ROS Decreased glutathion HO-1 Expression increased COX-2 Expression increased Secretion of Il-8 increased N/A N/A N/A N/A N/A LDH release Glutathion decreased HO-1 expression increased COX-2 expression increased Secretion of IL-8 N/A N/A N/A Decreased metabolic activity Decreased metabolic activity LDH release ROS Glutathion decreased Secretion of IL-8 increased N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Genotoxicity N/A N/A N/A N/A N/A N/A N/A No No No Comet assay 50 µg/cm2 N/A N/A N/A N/A N/A No No Comet assay 10 µg/cm2 ATP assay 50 µg/cm3 N/A No ATP assay 50 µg/cm3 No Comet assay 50 µg/cm2 No No No Comet assay 50 µg/cm2 N/A N/A N/A N/A N/A N/A Apical biological Effect Concentrations Tested STIS (mg/m3) 3 10 30 1 3 10 30 30 0.15 ± 0.05 0.57 ± 0.10 2.86 ± 0.82 0.54 ± 0.04 3.05 ± 1.05 10.1 ± 4.5 0.46 ± 0.11 2.08 ± 0.33 10.27 ± 1.44 0.5 ± 0.1 2.5 ± 0.2 10.9 ± 1.5 2 10 50 2.05 10.0 54.1 2.9 10.0 51.5 2.1 10.2 50.4 N/A 0.5 ± 2 5.3 ± 0.9 25.9 ± 6.0 0.48 ± 0 25.6 ± 6.0 0.5 2.5 10.0 0.5 2.5 10.0 0.5 ± 0.1 13.1 ± 0.7 53.4 ± 9.7 0.5 ± 0.1 2.4 ± 0.1 10.4 ± 1.3 N/A 2 10 50 0.5 2.0 10.0 1.9 ± 0.1 10.1 ± 1.0 50.5 ± 4.7 N/A N/A 2.0 ± 0.1 10.6 ± 0.3 52.2 ± 1.1 N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.6 2.4 3.3 6.3 13.2 NOAEC (mg/m3) 10 30 >30 <0.5 <2.5 <2.5 >10 2.5 >50 >50 >50 N/A <0.5 <0.5 <0.5 <0.5 >50 0.5 N/A <2 0.5 >50 N/A N/A >50 N/A N/A N/A N/A N/A N/A N/A N/A >10 0.6 Findings in BALF 30 mg/m3: increased PMN, marginally increased total cell count, increased MCP-1 and
  • steopontin
level No adverse effect No adverse effect 0.5 mg/m3: 2.5 mg/m3: 10 mg/m3: No adverse effect Slightly increased PMN neutrophils and lymphocytes No adverse effect No adverse effect No adverse effect N/A 0.5 mg/m3: neutrophil counts and cytokine- induced neutrophil chemoattrac tant-1 (CINC-1) increased 5 mg/m3: majority of BALF parameters increased (ALP, MCP1, CINC-1, M- CSF) 25 mg/m3: all parameters increased (ALP, NAG, MCP1, CINC-1, M- CSF) 0.5 mg/m3: MCP-1 and M-CSF increased 5 mg/m3: majority of BALF parameters increased (ALP, MCP1, CINC-1, M- CSF) 25 mg/m3: all parameters increased (ALP, NAG, MCP1, CINC-1, M- CSF) Changes of all cytological and biochemical parameters in BALF; increased levels of Changes of CINC-1, IFNγ, IL-1α, MCP-1, MCSF, in BALF and lung tissue Changes of all cytological and biochemical parameters in BALF, increased MCP-1 and CINC-1 in BALF, increased IL1-α in lung tissue No adverse effect Increased total cell counts and N/A No adverse effect 10 mg/m3: Increased PMN and GGT 50 mg/m3: Increase in total protein and all enzymes examined (GGT, LDH, ALP and NAG) No adverse effect N/A N/A No adverse effect N/A N/A N/A N/A N/A N/A N/A N/A No adverse effect A dose- dependent lung inflammatio n observed 50 mg/m3: Minimal
slide-11
SLIDE 11

Solubility of nanoparticles in realistic environments

Biological matrix Water, Lung, Intestine Nanomaterial

Ultrafiltration (UF) – ICP-MS

  • Accessible, (easy to use), cheap

methods based on ICP-MS, elementary detection

11

slide-12
SLIDE 12

Results

% Dissolved Concentration

12

slide-13
SLIDE 13

Approach failed in this project!

13

  • Detection (at low concentrations) is challenging:
  • polyatomic interference,
  • relatively low analytical recovery,
  • Complex matrix is very difficult, interactions with the matrix or filter
  • “Lessons learned”:
  • SP-ICP-MS: promising technique, but the size detection limit may be

limiting: thus not used here.

  • Very interesting developments in AF4 or HDC-SP-ICP-hrMS method

development outside of this project!

7 Materials

  • NanoGem Silica 15 nm
  • NanoGem Silica (amino) 15 nm
  • NanoGem Silica (phosphate) 15 nm
  • NM-202 (Silica)
  • NM-203 (Silica)
  • NM-104 (TiO2)
  • NM-105 (TiO2)
slide-14
SLIDE 14

Missing data to be addressed:

  • Cytochrome c assay for surface reactivity
  • Cytochrome c is oxidised by NP surface

14

N P

Ranking obtained from these results is in agreement with that from FRAS/FRAP assays CuO>Mn2O3>TiO2>CeO2>BaSO4

slide-15
SLIDE 15

Classification tree for a short-term inhalation study on rats

15

Descriptors selected: LUMO_C, Size, XPSNa

slide-16
SLIDE 16

NOAEC

Class NOAEC [mg/m

3]

TOX (1) ≤ 10 NTOX (2) > 10 NP LUMO_C Size XPSNa Split [S0] NOAEC [original value] NOAEC class [a priori] NOAEC class [predicted] Correct prediction BaSO4.NM220 0.128 32 T 50.00 2 2 TRUE SiO2.NH3

  • 1.031

15 T 50.00 2 2 TRUE SiO2.PEG

  • 1.031

15 V 50.00 2 2 TRUE SiO2.PO3

  • 1.031

15 0.5 T 50.00 2 2 TRUE ZrO2.ACR

  • 0.191

9 T 50.00 2 2 TRUE ZrO2.TOD

  • 0.191

9 V 50.00 2 2 TRUE DPP.NANO

  • 1.742

400 T 30.00 2 2 TRUE DPP.RED

  • 1.879

43 T 30.00 2 2 TRUE ZrO2

  • 0.191

42.5 V 10.00 1 2 FALSE DPP.BULK

  • 1.742

3000 T 10.00 1 1 TRUE SiO2.UNMOD

  • 1.031

15 1 T 2.50 1 1 TRUE TiO2.NM105

  • 3.319

50 0.5 V 1.00 1 1 TRUE TiO2.TLSF

  • 3.319

50 T 0.50 1 1 TRUE CeO2

  • 20.582

200 T 0.25 1 1 TRUE CeO2.Al

  • 20.582

81 V 0.25 1 1 TRUE CeO2.NM211 -20.582 12 T 0.25 1 1 TRUE CeO2.NM212 -20.582 40 T 0.25 1 1 TRUE ZrO2.NH3

  • 0.191

10 P 2 ZrO2.PEG

  • 0.191

9 P 2 T 1 2 1 6 2 6 T Accuracy 1.00 Error 0.00 Sensitivity 1.00 Specificity 1.00 V0 1 2 1 2 1 2 2 V0 Accuracy 0.80 Error 0.20 Sensitivity 1.00 Specificity 0.67

16

slide-17
SLIDE 17

NOAEC – multiple external validations

NP LUMO_C Size XPSNa NOAEC [original value] NOAEC class [a priori] S0 S1 S2 S3 S4 BaSO4.NM220 0.128 32 50 2 T T T V T SiO2.NH3

  • 1.031

15 50 2 T T T T V SiO2.PEG

  • 1.031

15 50 2 V T T T T SiO2.PO3

  • 1.031

15 0.5 50 2 T V T T T ZrO2.ACR

  • 0.191

9 50 2 T T V T T ZrO2.TOD

  • 0.191

9 50 2 V T T V T DPP.NANO

  • 1.742

400 30 2 T V T T V DPP.RED

  • 1.879

43 30 2 T T V T T ZrO2

  • 0.191

42.5 10 1 V T T V T DPP.BULK

  • 1.742

3000 10 1 T V T T V SiO2.UNMOD

  • 1.031

15 1 2.5 1 T T V T T TiO2.NM105

  • 3.319

50 0.5 1 1 V T T V T TiO2.TLSF

  • 3.319

50 0.5 1 T V T T V CeO2

  • 20.582

200 0.25 1 T T V T T CeO2.Al

  • 20.582

81 0.25 1 V T T V T CeO2.NM211

  • 20.582

12 0.25 1 T V T T V CeO2.NM212

  • 20.582

40 0.25 1 T T V T T ZrO2.NH3

  • 0.191

10 P P P P P ZrO2.PEG

  • 0.191

9 P P P P P Accuracy 80% 100% 100% 80% 100% Error 20% 0% 0% 20% 0% Sensitivity 100% 100% 100% 100% 100% Specificity 70% 100% 100% 70% 100%

17

slide-18
SLIDE 18

Towards Integrated Testing Strategies

18

Nanomaterial Protein carbonylation FRAS NOAEC BaSO4.NM220 I A I SiO2.NH3 A I I SiO2.PEG I I* I SiO2.PO3 A I I ZrO2.ACR I I* I ZrO2.TOD I I* I DPP.NANO I* A I DPP.RED I* A* I ZrO2 I* A* A DPP.BULK I* A A SiO2.UNMOD A I A TiO2.NM105 A A A TiO2.TLSF I* A* A CeO2 I* A* A CeO2.Al I* A* A CeO2.NM211 I* I A CeO2.NM212 I* A A ZrO2.NH3 I I* I* ZrO2.PEG I I* I*

slide-19
SLIDE 19

Conclusions

  • Optimization of analytical methods for determination of solubility in

complex matrices needed!

  • Decision trees can be used for refining descriptor selection and

setting specific numerical thresholds of structural features related to the change in biological properties

  • The identified key NP features (descriptors) can help in the design of

new nanomaterials, as they are the most relevant their safety

  • A predictive model is now proposed, can be applied in decision-

making framework for the grouping and testing of nanomaterials (DF4nanoGrouping)

  • Larger datasets on nanomaterials are needed: but now focus
  • n specific endpoints!
  • Consistent data and data quality remain important issues

19

slide-20
SLIDE 20

Thanks

20

Hans.bouwmeester@wur .nl